Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Tipo de documento: | Dissertação |
Idioma: | por |
Título da fonte: | Repositório Institucional da Universidade Federal do Ceará (UFC) |
Texto Completo: | http://www.repositorio.ufc.br/handle/riufc/8747 |
Resumo: | Deficiency of nitric oxide (NO) has been implicated as one of the main mechanisms of Endothelial dysfunction and erectile dysfunction. The search for new medications must be important to lessen the burden of this disease. The study evaluated the relaxation, in vitro, induced by a new drug of the Nitrosyl-Ruthenium complex (RUT-BPY-IMI) into strips of corpora cavernosa, taken from non-living human organ donor for transplantation. The strips were immersed in tissue baths in Krebs solution (pH7 .4, 37° C). They were contracted in 80 mm K + solution, and later again with Phenylephrine (PHE 10 μm) and concentration-response curves (10-12 to 10-4μM) were obtained. Initially the drug was compared with the vehicle (DMSO) and then with substances which have already been used in other studies. These drugs showed very good relaxing effects (SNP, BAY 41-2272 and Vardenafil). To clarify the mechanism by which this drug promotes relaxation, the following experiments were carried out: evaluation of relaxation achieved with the contraction with 80 mm K +, effect of an inhibitor of nitric oxide syntase (NOS), L-NAME (100 μm); addition of ODQ (30 μm), an inhibitor of the soluble GuanylateCyclase; a remover of the extracellular NO, bovine Hemoglobin (30 μm); Glibenclamide (10 μm), a potassium ion channel blocker ATP-dependent (KATP). The tissues exposed to the RUT-BPY-IMI, SNP and DMSO were frozen in liquid nitrogen to measure the amount of GMPc.The substance caused an EMAX relaxation in smooth muscle of the corpus cavernosum (EMAX = 112.92% ± 10.03% and pEC50 = 4.991 ± 0.1916), 70% more than the vehicle. Comparing RUT-BPY-IMI with the SNP, the drug studied showed as efficient as the SNP, there were no difference between both EMAX (p = 0,3437),. Compared with the BAY 41-2272, there was no statistical difference in any of the parameters studied (pEC50 and EMAX).. The EMAX achieved in concentration-response curve with 80 mm K + was about 20% lower than the curve with PHE (10 μm) (p = 0.0208). There was no inhibition of the relaxing effect of drug with L-NAME (p 0.05 >), or deviation from the curve to the right. The addition of ODQ (30 μm) to the bath, decreased 50% of the EMAX of the substance (p<0,05). The addition of bovine hemoglobin (30 μm) did not alter the capacity maximum relaxing substance (p<0,05). There was no inhibition or blockade of the maximum effect of the drug with Glibenclamide (10 μm) (p 0.05 >). The RUT-BPY-IMI tissue concentration of cGMP produced was 74% over the vehicle, and less than the SNP (p<0,05).RUT-BPY-IMI is a NO-donor, it produces a powerful relaxation of the smooth muscle of the corpus cavernosum. Probably, the substance does not induce NOS, acts by activating the soluble guanylateCyclase, which produces cGMP, releasing the intracellular NO. It seems that it does not activate potassium channels, and not act throw KATP. |
id |
UFC-7_445ecb012f51ac6355506cbba42ed787 |
---|---|
oai_identifier_str |
oai:repositorio.ufc.br:riufc/8747 |
network_acronym_str |
UFC-7 |
network_name_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository_id_str |
|
spelling |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanosComposite action of nitrosyl ruthenium complex-cis-Ru (bpy) 2IMn (NO) 3, in cavernous smooth muscle of humansÓxido NítricoCompostos de RutênioDeficiency of nitric oxide (NO) has been implicated as one of the main mechanisms of Endothelial dysfunction and erectile dysfunction. The search for new medications must be important to lessen the burden of this disease. The study evaluated the relaxation, in vitro, induced by a new drug of the Nitrosyl-Ruthenium complex (RUT-BPY-IMI) into strips of corpora cavernosa, taken from non-living human organ donor for transplantation. The strips were immersed in tissue baths in Krebs solution (pH7 .4, 37° C). They were contracted in 80 mm K + solution, and later again with Phenylephrine (PHE 10 μm) and concentration-response curves (10-12 to 10-4μM) were obtained. Initially the drug was compared with the vehicle (DMSO) and then with substances which have already been used in other studies. These drugs showed very good relaxing effects (SNP, BAY 41-2272 and Vardenafil). To clarify the mechanism by which this drug promotes relaxation, the following experiments were carried out: evaluation of relaxation achieved with the contraction with 80 mm K +, effect of an inhibitor of nitric oxide syntase (NOS), L-NAME (100 μm); addition of ODQ (30 μm), an inhibitor of the soluble GuanylateCyclase; a remover of the extracellular NO, bovine Hemoglobin (30 μm); Glibenclamide (10 μm), a potassium ion channel blocker ATP-dependent (KATP). The tissues exposed to the RUT-BPY-IMI, SNP and DMSO were frozen in liquid nitrogen to measure the amount of GMPc.The substance caused an EMAX relaxation in smooth muscle of the corpus cavernosum (EMAX = 112.92% ± 10.03% and pEC50 = 4.991 ± 0.1916), 70% more than the vehicle. Comparing RUT-BPY-IMI with the SNP, the drug studied showed as efficient as the SNP, there were no difference between both EMAX (p = 0,3437),. Compared with the BAY 41-2272, there was no statistical difference in any of the parameters studied (pEC50 and EMAX).. The EMAX achieved in concentration-response curve with 80 mm K + was about 20% lower than the curve with PHE (10 μm) (p = 0.0208). There was no inhibition of the relaxing effect of drug with L-NAME (p 0.05 >), or deviation from the curve to the right. The addition of ODQ (30 μm) to the bath, decreased 50% of the EMAX of the substance (p<0,05). The addition of bovine hemoglobin (30 μm) did not alter the capacity maximum relaxing substance (p<0,05). There was no inhibition or blockade of the maximum effect of the drug with Glibenclamide (10 μm) (p 0.05 >). The RUT-BPY-IMI tissue concentration of cGMP produced was 74% over the vehicle, and less than the SNP (p<0,05).RUT-BPY-IMI is a NO-donor, it produces a powerful relaxation of the smooth muscle of the corpus cavernosum. Probably, the substance does not induce NOS, acts by activating the soluble guanylateCyclase, which produces cGMP, releasing the intracellular NO. It seems that it does not activate potassium channels, and not act throw KATP.A deficiência de óxido nítrico (NO) tem sido implicada como um dos principais mecanismos de disfunção endotelial e de Disfunção erétil. A busca de novas medicações deve ser importante para diminuir a peso dessa doença. O estudo avaliou o relaxamento, in vitro, induzido por um novo fármaco doador de NO do complexo Nitrosil-Rutênio (RUT-BPY-IMI) em tiras de corpos cavernosos de humanos, retirados de doadores de órgãos para transplante não-vivos. Os tecidos, imersos em sistemas de banhos isolados em solução de Krebs (pH7,4, 37°C), foram contraídos em solução de K+ 80mM, e posteriormente novamente pré-contraídos com Fenilefrina (Phe 10µM) e curvas de concentração-resposta ( 1012 a 10-4) foram obtidas. Inicialmente o fármaco era comparado com o Veículo (DMSO) e com substâncias já utilizadas em outros estudos, que demonstraram bons efeitos relaxantes ( SNP, BAY 41-2272 e Vardenafila). Para esclarecer o mecanismo pela qual esse fármaco promove seu relaxamento, foram realizados os seguintes experimentos: avaliação do relaxamento alcançado com a contração com K+80mM, adição de um inibidos da Óxido Nítrico sintase (NOS), L-NAME (100µM); adição de ODQ (30µM), um inibidor da GuanilatoCiclase solúvel; um removedor de NO extracelular, Hemoglobina bovina (30µM); Glibenclamida ( 10µM), um bloqueador de canais de íons potássio ATP-dependente (Katp). Os tecidos expostos ao RUT-BPY-IMI, SNP e DMSO foram congelados em nitrogênio líquido para mensurar a quantidade de GMPc. A substância provocou um relaxamento máximo (Emax) na musculatura lisa de corpo cavernoso importante ( Emax= 112,92% ±10,03% e pEC50=4,991±0,1916), 60% a mais que o veículo. Comparando RUT-BPy-IMI com o SNP, a droga estudada mostrou tão eficiente como o SNP, não mostrando diferença entre os dois Emax (p=0,3437). Já com o BAY 41-2272, não houve diferença estatística em nenhum dos parâmetros estudados (Emax e pEC50)..O Emax alcançado na curva concentração- resposta com K+ 80mM foi cerca de 20% menor que a curva com Phe (10µM) (p=0,0208). Não houve inibição do efeito relaxante máximo da droga com L-NAME (p>0,05), ou desvio da curva para a direita. A adição ODQ (30µM) ao banho diminuiu em cerca de 50% o Emax da substância (p<0,05). Já a adição da hemoglobina bovina (30µM) não alterou a capacidade relaxante máxima da substância (p<0,05). Não houve bloqueio de efeito máximo do fármaco com a Glibenclamida (10µM) (p>0,05). O RUT-BPY produziu uma concentração intracelular de GMPc 74% maior que o veículo, e menor que o SNP O RUT-BPY-IMI é uma substância doadora NO, potente relaxadora da musculatura lisa do corpo cavernoso humano. A substância possivelmente não induz NOS, atua, provavelmente ativando a guanilatociclase solúvel, produzindo GMPc, liberando NO intracelular. Não parece atuar nos canais de potássio, e não atuam no KatpSilva , Lúcio Flávio GonzagaLeitão Júnior, Alexandre Sabóia2014-08-19T16:07:45Z2014-08-19T16:07:45Z2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfLEITÃO JÚNIOR, Alexandre Sabóia. Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos. 2013. 75 f. Dissertação (Mestrado em Cirurgia) - Universidade Federal do Ceará. Faculdade de Medicina, Fortaleza, 2013.http://www.repositorio.ufc.br/handle/riufc/8747porreponame:Repositório Institucional da Universidade Federal do Ceará (UFC)instname:Universidade Federal do Ceará (UFC)instacron:UFCinfo:eu-repo/semantics/openAccess2018-12-13T19:01:00Zoai:repositorio.ufc.br:riufc/8747Repositório InstitucionalPUBhttp://www.repositorio.ufc.br/ri-oai/requestbu@ufc.br || repositorio@ufc.bropendoar:2024-09-11T18:52:53.376738Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC)false |
dc.title.none.fl_str_mv |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos Composite action of nitrosyl ruthenium complex-cis-Ru (bpy) 2IMn (NO) 3, in cavernous smooth muscle of humans |
title |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos |
spellingShingle |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos Leitão Júnior, Alexandre Sabóia Óxido Nítrico Compostos de Rutênio |
title_short |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos |
title_full |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos |
title_fullStr |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos |
title_full_unstemmed |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos |
title_sort |
Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos |
author |
Leitão Júnior, Alexandre Sabóia |
author_facet |
Leitão Júnior, Alexandre Sabóia |
author_role |
author |
dc.contributor.none.fl_str_mv |
Silva , Lúcio Flávio Gonzaga |
dc.contributor.author.fl_str_mv |
Leitão Júnior, Alexandre Sabóia |
dc.subject.por.fl_str_mv |
Óxido Nítrico Compostos de Rutênio |
topic |
Óxido Nítrico Compostos de Rutênio |
description |
Deficiency of nitric oxide (NO) has been implicated as one of the main mechanisms of Endothelial dysfunction and erectile dysfunction. The search for new medications must be important to lessen the burden of this disease. The study evaluated the relaxation, in vitro, induced by a new drug of the Nitrosyl-Ruthenium complex (RUT-BPY-IMI) into strips of corpora cavernosa, taken from non-living human organ donor for transplantation. The strips were immersed in tissue baths in Krebs solution (pH7 .4, 37° C). They were contracted in 80 mm K + solution, and later again with Phenylephrine (PHE 10 μm) and concentration-response curves (10-12 to 10-4μM) were obtained. Initially the drug was compared with the vehicle (DMSO) and then with substances which have already been used in other studies. These drugs showed very good relaxing effects (SNP, BAY 41-2272 and Vardenafil). To clarify the mechanism by which this drug promotes relaxation, the following experiments were carried out: evaluation of relaxation achieved with the contraction with 80 mm K +, effect of an inhibitor of nitric oxide syntase (NOS), L-NAME (100 μm); addition of ODQ (30 μm), an inhibitor of the soluble GuanylateCyclase; a remover of the extracellular NO, bovine Hemoglobin (30 μm); Glibenclamide (10 μm), a potassium ion channel blocker ATP-dependent (KATP). The tissues exposed to the RUT-BPY-IMI, SNP and DMSO were frozen in liquid nitrogen to measure the amount of GMPc.The substance caused an EMAX relaxation in smooth muscle of the corpus cavernosum (EMAX = 112.92% ± 10.03% and pEC50 = 4.991 ± 0.1916), 70% more than the vehicle. Comparing RUT-BPY-IMI with the SNP, the drug studied showed as efficient as the SNP, there were no difference between both EMAX (p = 0,3437),. Compared with the BAY 41-2272, there was no statistical difference in any of the parameters studied (pEC50 and EMAX).. The EMAX achieved in concentration-response curve with 80 mm K + was about 20% lower than the curve with PHE (10 μm) (p = 0.0208). There was no inhibition of the relaxing effect of drug with L-NAME (p 0.05 >), or deviation from the curve to the right. The addition of ODQ (30 μm) to the bath, decreased 50% of the EMAX of the substance (p<0,05). The addition of bovine hemoglobin (30 μm) did not alter the capacity maximum relaxing substance (p<0,05). There was no inhibition or blockade of the maximum effect of the drug with Glibenclamide (10 μm) (p 0.05 >). The RUT-BPY-IMI tissue concentration of cGMP produced was 74% over the vehicle, and less than the SNP (p<0,05).RUT-BPY-IMI is a NO-donor, it produces a powerful relaxation of the smooth muscle of the corpus cavernosum. Probably, the substance does not induce NOS, acts by activating the soluble guanylateCyclase, which produces cGMP, releasing the intracellular NO. It seems that it does not activate potassium channels, and not act throw KATP. |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013 2014-08-19T16:07:45Z 2014-08-19T16:07:45Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/masterThesis |
format |
masterThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
LEITÃO JÚNIOR, Alexandre Sabóia. Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos. 2013. 75 f. Dissertação (Mestrado em Cirurgia) - Universidade Federal do Ceará. Faculdade de Medicina, Fortaleza, 2013. http://www.repositorio.ufc.br/handle/riufc/8747 |
identifier_str_mv |
LEITÃO JÚNIOR, Alexandre Sabóia. Ação do composto do complexo nitrosil-rutênio cis-[Ru(bpy)2IMn(NO)]+3, na musculatura lisa cavernosa de humanos. 2013. 75 f. Dissertação (Mestrado em Cirurgia) - Universidade Federal do Ceará. Faculdade de Medicina, Fortaleza, 2013. |
url |
http://www.repositorio.ufc.br/handle/riufc/8747 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da Universidade Federal do Ceará (UFC) instname:Universidade Federal do Ceará (UFC) instacron:UFC |
instname_str |
Universidade Federal do Ceará (UFC) |
instacron_str |
UFC |
institution |
UFC |
reponame_str |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
collection |
Repositório Institucional da Universidade Federal do Ceará (UFC) |
repository.name.fl_str_mv |
Repositório Institucional da Universidade Federal do Ceará (UFC) - Universidade Federal do Ceará (UFC) |
repository.mail.fl_str_mv |
bu@ufc.br || repositorio@ufc.br |
_version_ |
1813028982132572160 |